不同服药频率四联方案在根除治疗幽门螺杆菌的应用效果

摘要
图/表
参考文献(18)
相关文章 (15)

全文: PDF (456 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨不同服药频率四联方案在根除治疗幽门螺杆菌的应用效果。方法选取2018年8月至2020年7月在深圳市龙岗中心医院门诊确诊的幽门螺杆菌感染的160 例消化性溃疡患者作为研究对象，采用随机数字法将其分为观察组（80 例）和对照组（80 例），观察组采用每天4 次服药的四联方案（艾司奥美拉唑镁+枸橼酸铋钾+克拉霉素+左氧氟沙星），对照组采用每天两次服药的相同四联方案，疗程均为14 d，比较两组幽门螺杆菌的根除率及不良反应发生率。结果观察组幽门螺杆菌根除率高于对照组，差异有统计学意义（P<0.05），观察组不良反应总发生率低于对照组，差异有统计学意义（P<0.05）。结论每天4 次服药的改良四联方案可提高患者的幽门螺杆菌根除率，安全性更好，尤其适用于青霉素过敏患者。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：艾司奥美拉唑镁, 高剂量, 克拉霉素, 左氧氟沙星, 幽门螺杆菌, 根除率

Abstract：Objective To investigate the application effect of quadruple regimen with different medication frequency in the eradication of Helicobacter pylori. Methods A total of 160 patients of peptic ulcer diagnosed with helicobacter pylori infection in the outpatient department of Shenzhen Longgang Central Hospital from August 2018 to July 2020 were selected as the research subjects and divided into observation group (80 cases) and control group (80 cases) by the random number table method. The observation group was given a quadruple regimen (Esomeprazole Magnesium + Bismuth Potassium Citrate + Clarithromycin + Levofloxacin) four times daily, while the control group was given the same quadruple regimen twice daily for 14 days, and the eradication rate of Helicobacter pylori and the incidence of adverse reactions were compared between the two groups. Results The eradication rate of Helicobacter pylori in the observation group was higher than that in the control group, the difference was statistically significant (P<0.05), and the total incidence of adverse reactions in the observation group was lower than that in the control group, the difference was statistically significant (P<0.05). Conclusions A modified quadruple regimen of four times daily increased the eradication rate of Helicobacter pylori，and with the better safety，Which is especially suitable for patients with penicillin allergy.

Key words： Esomeprazole High dose Clarithromycin Levofloxacin Helicobacter pylori Eradication rate

基金资助:广东省深圳市龙岗区医疗卫生科技计划项目（LGKCYLWS2020008）

引用本文:

曾小辉；黄丽玲；彭颂兴. 不同服药频率四联方案在根除治疗幽门螺杆菌的应用效果[J]. 中国当代医药, 2022, 29(13): 36-39.
ZENG Xiaohui1 HUANG Liling2 PENG Songxing. Clinical effect of quadruple regimen with different frequency in the eradication of Helicobacter pylori. 中国当代医药, 2022, 29(13): 36-39.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2022/V29/I13/36

[1]	中华医学会消化病学分会幽门螺杆菌和消化性溃疡学组，全国幽门螺杆菌研究协作组，刘文忠，等.第五次全国幽门螺杆菌感染处理共识报告[J].中华内科杂志，2017，56（7）：532-545.
[2]	Malfertheiner P，Megraud F，O′Morain CA，et al.Management of Helicobacter pylori infection the Maastricht V/Florence Consensus Report[J].Gut，2017，66（1）：6-30.
[3]	Sapmaz F，Kalkan IH，Atasoy P，et al.A non-inferiority study：modified dual therapy consisting higher does of rabeprazole is as successful as standard quadruple therapy in eradication of helicobacter pylori[J].Am J Ther，2017，24（4）：e393-e398.
[4]	索宝军，田雪丽，李彩玲，等.雷贝拉唑和阿莫西林双联2 周方案在幽门螺杆菌感染初治患者中的疗效观察[J].中华医学杂志，2019，99（48）：3781-3785.
[5]	Tai WC，Liang CM，Kuo CM，et al.A 14 day esomeprazoleand amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan：a prospective randomized trial[J].J Antimicrob Chemother，2019，74（6）：1718-1724.
[6]	黄继平，黄艳娟，袁小刚，等.深圳龙岗地区幽门螺杆菌耐药状况分析及耐药对治疗的影响[J].实用医学杂志，2015，31（14）：2382-2384.
[7]	Zhang YX，Zhou LY，Song ZQ，et al.Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing：a prospective serial study[J].World J Gastroenterol，2015，21（9）：2786-2792.
[10]	吕涛，倪丽，吴娟，等.深圳幽门螺杆菌根除率变化和耐药分析多中心研究[J].中华消化杂志，2020，40（8）：557-561.
[11]	陈丽萍，金雷.大剂量艾司奥美拉唑镁对幽门螺杆菌相关性胃炎的治疗效果分析[J].中国医学前沿杂志（电子版），2019，11（1）：83-86.
[8]	Zhou L，Zhang J，Song Z，et al.Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment：A Randomized Trial[J].Helicobacter，2016，21（2）：91-99.
[9]	Hong J，Shu X，Liu D，et al.Antibiotic resistance and CYP2C19 polymorphisms affect the efficacy of concomitant therapies for Helicobacter pylori infection：an open -label，randomized，single-centre clinical trial[J].J Antimicrob Chemother，2016，71（8）：2280-2285.
[12]	Yang X，Wang JX，Han SX，et al.High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment：A systematic review and meta-analysis[J].Medicine（Baltimore），2019，98（7）：e14396.
[13]	Yu L，Luo L，Long X，et al.High-dose PPI-amoxicillin dual therapy with or without bismuth for firstline Helicobacter pylori therapy：A randomized trial[J].Helicobacter，2019，24（4）：e12596.
[14]	Song ZQ，Zhou LY，Xue Y，et al.A comparative study of 14-day dual therapy （esomeprazole and amoxicillin four times daily）and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication：A randomized trial[J].Helicobacter，2020，25（6）：e12762.
[15]	Yang J，Zhang Y，Fan L，et al.Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori[J].Am J Gastroenterol，2019，114（3）：437-445.
[16]	Suzuki S，Gotoda T，Kusano C，et al.Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment：a multicentre randomised trial in Japan[J].Gut，2020，69（6）：1019-1026.
[17]	Gotoda T，Kusano C，Suzuki S，et al.Clinical impact of vonoprazan-based dual therapy with amoxicillin for H.pylori infection in a treatment-naive cohort of junior high school students in Japan[J].J Gastroenterol，2020，55（10）：969-976.
[18]	Furuta T，Yamade M，Kagami T，et al.Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan，amoxicillin and clarithromycin for eradication of helicobacter pylori[J].Digestion，2020，101（6）：743-751.